A gene mutation in the Janus kinase 2 (JAK2) gene is common in myelofibrosis cases and can help determine prognosis and treatment.
Ruxolitinib is a medicine that is a kinase inhibitor, used to treat myelofibrosis with the JAK2 genetic mutation.
Currently, allogeneic hematopoietic cell transplant (HCT) is the only chance for a cure, however it is not an option for most patients.
Fedratinib is a medicine that is called a kinase inhibitor. It targets the JAK2 genetic mutation commonly detected in myelofibrosis patients.
Anemia is very uncommon in myelofibrosis patients.